A(1-7) Reduces Pathologies Associated with SLE in MRL-lpr Mice

The study demonstrated that daily treatment with angiotensin (1-7) [A(1-7)] for 6 weeks significantly reduced various pathologies associated with Systemic Lupus Erythematosus (SLE) in MRL-lpr mice. The treatment led to lower levels of proteinuria, reduced glomerular pathologies, smaller lymph nodes, decreased levels of anti-dsDNA IgG, and less severe cutaneous pathologies, including reduced inflammation and hair loss, compared to saline-treated MRL-lpr mice. These findings suggested that A(1-7) could be a promising therapeutic target for SLE.